Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
This Phase 2 study will confirm the efficacy and safety of EPX-100 with children suffering from Dravet Syndrome. The Company is now recruiting patients for this clinical study, collaborated with GreenLight Clinical.
Lead Product(s): Clemizole hydrochloride
Therapeutic Area: Neurology Product Name: EPX-100
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Epygenix Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020